JPH06239730A - Whitening cosmetic - Google Patents
Whitening cosmeticInfo
- Publication number
- JPH06239730A JPH06239730A JP5047555A JP4755593A JPH06239730A JP H06239730 A JPH06239730 A JP H06239730A JP 5047555 A JP5047555 A JP 5047555A JP 4755593 A JP4755593 A JP 4755593A JP H06239730 A JPH06239730 A JP H06239730A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- effect
- action
- cosmetic
- glabridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002087 whitening effect Effects 0.000 title claims abstract description 27
- 239000002537 cosmetic Substances 0.000 title claims abstract description 24
- 239000000203 mixture Substances 0.000 claims abstract description 18
- LBQIJVLKGVZRIW-ZDUSSCGKSA-N glabridin Chemical compound C1([C@H]2CC3=CC=C4OC(C=CC4=C3OC2)(C)C)=CC=C(O)C=C1O LBQIJVLKGVZRIW-ZDUSSCGKSA-N 0.000 claims abstract description 13
- 229940093767 glabridin Drugs 0.000 claims abstract description 13
- PMPYOYXFIHXBJI-ZDUSSCGKSA-N glabridin Natural products C1([C@H]2CC=3C=CC4=C(C=3OC2)CCC(O4)(C)C)=CC=C(O)C=C1O PMPYOYXFIHXBJI-ZDUSSCGKSA-N 0.000 claims abstract description 13
- LBQIJVLKGVZRIW-UHFFFAOYSA-N glabridine Natural products C1OC2=C3C=CC(C)(C)OC3=CC=C2CC1C1=CC=C(O)C=C1O LBQIJVLKGVZRIW-UHFFFAOYSA-N 0.000 claims abstract description 13
- 210000002966 serum Anatomy 0.000 claims abstract description 9
- 230000003544 deproteinization Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 15
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract description 6
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract description 4
- 206010040880 Skin irritation Diseases 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 4
- 231100000475 skin irritation Toxicity 0.000 abstract description 4
- 230000036556 skin irritation Effects 0.000 abstract description 4
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 230000004054 inflammatory process Effects 0.000 abstract description 3
- 239000007787 solid Substances 0.000 abstract description 3
- 230000002209 hydrophobic effect Effects 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract 4
- 230000003061 melanogenesis Effects 0.000 abstract 2
- 230000000845 anti-microbial effect Effects 0.000 abstract 1
- 230000003064 anti-oxidating effect Effects 0.000 abstract 1
- 230000002500 effect on skin Effects 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 230000019612 pigmentation Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 27
- 238000012360 testing method Methods 0.000 description 26
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- 239000000523 sample Substances 0.000 description 7
- 206010015150 Erythema Diseases 0.000 description 6
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 6
- 231100000321 erythema Toxicity 0.000 description 6
- 102000003425 Tyrosinase Human genes 0.000 description 5
- 108060008724 Tyrosinase Proteins 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- -1 aliphatic alcohols Chemical class 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000202807 Glycyrrhiza Species 0.000 description 3
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 3
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 210000000245 forearm Anatomy 0.000 description 3
- 229940010454 licorice Drugs 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 2
- 229960000990 monobenzone Drugs 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000002884 skin cream Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 150000003700 vitamin C derivatives Chemical class 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 229920000298 Cellophane Polymers 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000170 anti-cariogenic effect Effects 0.000 description 1
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 238000011597 hartley guinea pig Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003883 substance clean up Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Landscapes
- Cosmetics (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は、皮膚安全性に優れ、紫
外線による皮膚の炎症を予防する効果と色黒の皮膚を速
やかに淡色化する効果とを有する美白化粧料に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a whitening cosmetic composition which is excellent in skin safety and has an effect of preventing skin inflammation caused by ultraviolet rays and an effect of rapidly lightening dark skin.
【0002】[0002]
【従来の技術及び発明が解決しようとする課題】紫外線
により皮膚は炎症(紅斑)を起こし種々の因子が放出さ
れメラノサイトを刺激する。これにより色調は変化し黒
化する。この黒化は、メラノサイトにおいて産生され表
皮細胞に受け渡されるメラニンの過剰生産が原因であ
り、メラニンはチロシンが酸化されて産生される。2. Description of the Related Art UV rays cause inflammation (erythema) on the skin, and various factors are released to stimulate melanocytes. As a result, the color tone changes and blackens. This blackening is caused by the overproduction of melanin produced in melanocytes and delivered to epidermal cells, and melanin is produced by the oxidation of tyrosine.
【0003】従来より、皮膚の黒化やしみ、そばかすを
防ぎ本来の白い肌を保つために、この酸化を防止するビ
タミンCの塩や脂肪酸誘導体、更にハイドロキノンモノ
ベンジルエーテル、過酸化水素等を配合した美白化粧料
が提案されている。Conventionally, in order to prevent skin blackening, stains and freckles and maintain the original white skin, vitamin C salts and fatty acid derivatives which prevent this oxidation, hydroquinone monobenzyl ether, hydrogen peroxide and the like are blended. A whitening cosmetic product has been proposed.
【0004】しかし、これらの美白化粧料中にビタミン
C誘導体を配合すると、保存安定性が不充分であるか、
紫外線による炎症抑制効果、美白効果が充分に認められ
ないことが多い。一方、美白化粧料中にハイドロキノン
モノベンジルエーテル等を配合すると、色黒の肌を淡色
化する効果はあるが、皮膚の安全性上に問題がある等の
欠点がある。このように、炎症抑制効果、美白効果に優
れ且つ皮膚安全性が高く、保存安定性が十分な美白化粧
料を得ることは困難を極めている。[0004] However, if the vitamin C derivative is added to these whitening cosmetics, the storage stability is insufficient,
In many cases, the effects of suppressing inflammation and whitening by ultraviolet rays are not sufficiently observed. On the other hand, blending hydroquinone monobenzyl ether or the like into a whitening cosmetic has the effect of lightening dark skin, but has the drawback of causing a problem in terms of skin safety. As described above, it is extremely difficult to obtain a whitening cosmetic composition having excellent anti-inflammatory effect and whitening effect, high skin safety, and sufficient storage stability.
【0005】血清除蛋白物を単独で配合した場合、抗炎
症効果を有するものの、その使用感は満足するものでは
なかった。When the serum deproteinization product was blended alone, it had an anti-inflammatory effect, but its usability was not satisfactory.
【0006】また、甘草の疎水性成分であるグラブリジ
ンを、単独で配合した場合、抗菌作用、抗酸化作用、抗
う触作用、抗プラスミン作用、メラニン生成抑制作用を
有することが確認されている。しかし、美白効果は優れ
ているもののその使用感は満足するものではなかった。It has been confirmed that when glabridin, which is a hydrophobic component of licorice, is blended alone, it has an antibacterial action, an antioxidant action, an anticariogenic action, an antiplasmin action and a melanin production inhibiting action. However, although the whitening effect was excellent, the feeling of use was not satisfactory.
【0007】[0007]
【課題を解決するための手段】本発明者らは、このよう
な状況に鑑み、従来技術の難点を改良せんとして鋭意研
究を重ねた結果、後記発明が、炎症抑制効果と美白効果
に優れ、且つ皮膚安全性が高く、使用感の優れた美白化
粧料となることを見いだし、本発明の完成に至った。In view of such a situation, the inventors of the present invention have conducted intensive studies to improve the drawbacks of the prior art, and as a result, the invention described below has an excellent anti-inflammatory effect and a whitening effect. Further, they have found that the whitening cosmetic composition has high skin safety and excellent usability, and thus completed the present invention.
【0008】即ち、本発明は、炎症抑制効果、美白効果
に優れ、且つ皮膚安全性が高く、使用感の優れた美白化
粧料を提供することを目的とするものである。[0008] That is, an object of the present invention is to provide a whitening cosmetic composition which is excellent in anti-inflammatory effect and whitening effect, has high skin safety and is excellent in usability.
【0009】上記の目的を達成するために本発明の美白
化粧料は、次のような構成をとる。即ち、本発明はイン
ドメタシンとグラブリジンとを含有することを特徴とす
る美白化粧料である。In order to achieve the above object, the whitening cosmetic composition of the present invention has the following constitution. That is, the present invention is a whitening cosmetic characterized in that it contains indomethacin and glabridin.
【0010】本発明の美白化粧料に用いられる血清除蛋
白物は、例えば、以下の方法で得ることができる。即
ち、原料となる幼牛等の血液の繊維素を除きアセトンを
加え、次にアセトン:エーテル=1:1の混合物を加
え、遠心分離後乾燥させる。その乾燥物に蒸留水、トリ
プシンを加えpH8、370 Cで発酵させる。発酵後セ
ロファン透析を行い、濃縮して抽出物を得るなどの方法
がある。得られた抽出物は黄色味を帯びた透明な液体で
固形物量としては4〜5%含まれる。これらの抽出物は
ソルコセリル(ソルコバーゼル社製)、又はエスアール
71(ボトガー社製)として購入することができる。The serum deproteinized product used in the whitening cosmetic composition of the present invention can be obtained, for example, by the following method. That is, the fibrin of blood such as a cow as a raw material is removed, acetone is added, and then a mixture of acetone: ether = 1: 1 is added, followed by centrifugation and drying. Distilled water and trypsin are added to the dried product, and fermentation is performed at pH 8 and 370C. After fermentation, cellophane dialysis is carried out and concentrated to obtain an extract. The obtained extract is a yellowish transparent liquid and contains 4 to 5% of solids. These extracts can be purchased as Solcoceryl (manufactured by Solco Basel) or S-71 (manufactured by Botoger).
【0011】本発明の皮膚化粧料に用いられるグラブリ
ジンは、天然には、甘草の一種であるGlycyrrhiza glab
a Linne var.(通称ロシア・アフガン・トルコカンゾ
ウ)に微量含まれている。グラブリジンの製造法として
は、甘草の根又は、その水抽出残渣(例えばグリチルリ
チンを抽出した残渣)を有機溶媒で抽出する。抽出溶媒
としては、メタノール、エタノール等の低級脂肪族アル
コール、アセトン等の低級脂肪族ケトン、ジオキサン、
エチルエーテル等のエーテル類、塩化メチレン等のハロ
ゲン化炭化水素類、酢酸エチル等のエステル類、ヘキサ
ン等の炭化水素類の有機溶媒の1種又は2種以上の混合
物を使用することができる。抽出する甘草は、約5〜1
5倍量の上記溶媒に浸漬し、常温で静置するか還流下に
加熱する。抽出液から溶媒を留去して得られる抽出物
は、通常5〜10%程度のグラブリジンを含有してい
る。精製は、例えば順相シリカゲルカラムクロマトグラ
フィー及び逆相シリカゲルカラムクロマトグラフィーに
より処理した後、アセトンから再結晶する方法により、
比較的容易にグラブリジンの純品を得ることができる。
精製は他にも合成吸着体によるカラムクロマトグラフィ
ー等の任意の有機化合物の精製手段を採用して行なうこ
とができる。Glabridin used in the skin cosmetic of the present invention is naturally a kind of licorice, Glycyrrhiza glab.
It is contained in a small amount in a Linne var. (commonly known as Russian, Afghan and Turkish liquorice). As a method for producing glabridin, licorice root or a water extraction residue thereof (for example, a residue obtained by extracting glycyrrhizin) is extracted with an organic solvent. As the extraction solvent, lower aliphatic alcohols such as methanol and ethanol, lower aliphatic ketones such as acetone, dioxane,
One or a mixture of two or more ethers such as ethyl ether, halogenated hydrocarbons such as methylene chloride, esters such as ethyl acetate, and hydrocarbons such as hexane can be used. Licorice to be extracted is about 5-1
It is dipped in 5 times the amount of the above solvent and left standing at room temperature or heated under reflux. The extract obtained by distilling the solvent off from the extract usually contains about 5 to 10% of glabridin. Purification is performed by, for example, a method of treating by normal phase silica gel column chromatography and reverse phase silica gel column chromatography, and then recrystallizing from acetone,
Pure glabridin can be obtained relatively easily.
In addition, purification can be performed by adopting any organic compound purification means such as column chromatography using a synthetic adsorbent.
【0012】血清除蛋白物の本発明の美白化粧料中への
配合量は、乾燥固形物量で、総量を基準として、好まし
くは、0.001〜3.0wt%である。[0012] The amount of the serum deproteinized protein in the whitening cosmetic composition of the present invention is a dry solid amount, and is preferably 0.001 to 3.0 wt% based on the total amount.
【0013】グラブリジンの本発明の美白化粧料中への
配合量は、総量を基準として、好ましくは、0.001
〜1.0wt%である。The amount of glabridin incorporated into the whitening cosmetic composition of the present invention is preferably 0.001 based on the total amount.
~ 1.0 wt%.
【0014】血清除蛋白物、グラブリジンの配合量が
0.001w%未満では本発明の目的とする効果に充分
ではなく、血清除蛋白物の配合量が3.0w%、グラブ
リジンの配合量が1.0w%をそれぞれ超えても、その
増加分に見合った効果の向上は望めず、使用時の感触が
悪くなり易く、個々の剤型を保持し難くなる。If the amount of the serum deproteinized product and glabridin is less than 0.001 w%, the effect of the present invention is not sufficient, and the amount of the serum deproteinized protein is 3.0 w% and the amount of glabridin is 1%. Even if it exceeds 0.0 w%, the effect corresponding to the increase cannot be expected to be improved, the feel at the time of use tends to deteriorate, and it becomes difficult to hold individual dosage forms.
【0015】本発明の美白化粧料は、常法に従って、ロ
ーション類、乳液類、クリーム類、パック類等の剤型に
することが可能である。The whitening cosmetic composition of the present invention can be formulated into lotions, emulsions, creams, packs and the like according to a conventional method.
【0016】尚、本発明の美白化粧料には、色素、香
料、防腐剤、界面活性剤、顔料等を本発明の目的を達成
する範囲で適宜配合することができる。In the whitening cosmetic composition of the present invention, dyes, fragrances, preservatives, surfactants, pigments and the like can be appropriately added within the range to achieve the object of the present invention.
【0017】[0017]
【実施例】以下、実施例及び比較例に基づいて本発明を
詳細に説明する。EXAMPLES The present invention will be described in detail below based on examples and comparative examples.
【0018】実施例に記載されている(1)チロシナー
ゼ活性阻害試験、(2)皮膚色明度回復試験、(3)美
白実用試験、(4)紫外線紅斑抑制試験、(5)光パッ
チ試験、(6)官能試験の各試験法は次の通りである。(1) Tyrosinase activity inhibition test, (2) Skin color lightness recovery test, (3) Whitening practical test, (4) UV erythema inhibition test, (5) Photopatch test, () described in Examples. 6) Each test method of the sensory test is as follows.
【0019】(1)チロシナーゼ活性阻害試験 マックルベイン緩衝液(pH6.8)1mlに0.3m
g/ml濃度のチロシン溶液に各濃度の試料溶液を加
え、37℃にて10分間の予備保温を行う。これに1m
g/ml濃度のチロシナーゼ(シグマ社製)0.1ml
を加え37℃にて15分間加温した後、分光光度計を用
いて波長475nmにて吸光度(A)を測定した。一
方、チロシナーゼの代わりに緩衝液0.1mlを加えた
ものの吸光度(B)、試料溶液の代わりに緩衝液0.1
ml加えたものの吸光度(C)、更に試料溶液とチロシ
ナーゼの代わりに緩衝液0.2ml加えたものの吸光度
(D)をそれぞれ測定して、下式に従い阻害率(%)を
算出した。(1) Tyrosinase activity inhibition test 0.3 m per 1 ml of McClubein buffer (pH 6.8)
A sample solution of each concentration is added to a tyrosine solution of g / ml concentration, and pre-incubation is performed at 37 ° C for 10 minutes. 1m to this
0.1 ml of tyrosinase (manufactured by Sigma) at a concentration of g / ml
Was added and heated at 37 ° C. for 15 minutes, and then the absorbance (A) was measured at a wavelength of 475 nm using a spectrophotometer. On the other hand, the absorbance (B) of 0.1 ml of buffer solution added in place of tyrosinase, 0.1% buffer solution in place of the sample solution.
The absorbance (C) of the solution added with ml and the absorbance (D) of the sample solution added with 0.2 ml of the buffer solution instead of tyrosinase were measured, and the inhibition rate (%) was calculated according to the following formula.
【0020】阻害率(%)={1−(A−B)/(C−
D)} ×100Inhibition rate (%) = {1- (AB) / (C-
D)} × 100
【0021】(2)皮膚色明度回復試験 被試験者20名の上腕内側部皮膚にUVA、UVB領域
の紫外線の最小紅斑量を3日間連続照射し照射終了後、
試料塗布部とベース塗布部皮膚の基準明度(V0 値、V
0 ´値)を測定した。引き続いて、1日3回ずつ4週間
連続で塗布し、照射開始1、2、4週間後の試料塗布部
と、ベース塗布部皮膚の皮膚明度(Vn値、Vn ´値)
を測定して、下記の判定基準により皮膚色の回復評価を
行った。(2) Skin Color Brightness Recovery Test After the irradiation of the minimum erythema amount of UV rays in the UVA and UVB regions to the skin of the upper arm of 20 test subjects for 3 days continuously,
Reference lightness (V0 value, V of skin of sample application part and base application part)
0'value) was measured. Subsequently, the skin lightness (Vn value, Vn 'value) of the sample-applied part and the base-applied part 1 to 2 weeks after the start of irradiation was applied 3 times a day for 4 consecutive weeks
Was measured, and skin color recovery was evaluated according to the following criteria.
【0022】尚、皮膚の明度(マンセル表示系V値)
は、高速分光色彩計で測定して得られX、Y、Z値より
算出した。又、評価は被試験者20名の4週間後の評価
点の平均値で示した。The brightness of the skin (V value of Munsell display system)
Was calculated from X, Y, and Z values obtained by measurement with a high-speed spectrocolorimeter. The evaluation is shown by the average value of the evaluation points of 20 test subjects after 4 weeks.
【0023】[0023]
【表1】 024】(3)美白実用試験 夏期の太陽光に3時間(1日1.5時間で2日間)曝さ
れた被試験者20名の前腕屈側部皮膚を対象として、左
前腕屈側部皮膚には太陽光に曝された日より、試料を、
右前腕屈側部皮膚には太陽光に曝された日よりベースを
朝夕1回ずつ13週連続塗布した。[Table 1] (3) Whitening Practical Test Left forearm flexion side skin of 20 test subjects exposed to summer sunlight for 3 hours (1.5 hours a day for 2 days). Samples from the day of exposure to sunlight,
The base was applied to the right forearm flexion side skin once a day in the morning and continuously for 13 weeks from the day of exposure to sunlight.
【0025】尚、評価はベース塗布部より試料塗布部の
効果を確認された被験者の人数で示した。The evaluation was shown by the number of test subjects whose effect of the sample application section was confirmed by the base application section.
【0026】(4)紫外線紅斑抑制試験 除毛したハートレー系モルモット10匹の背部皮膚にU
VB領域の紫外線の最小紅斑量の2倍を各2ヶ所ずつ照
射を行う。24時間前と照射直後に試料を塗布し、試料
塗布部位とベース塗布部位を設定して、24時間後に紅
斑の状態を下記判定基準に従い評価を行った。(4) UV Erythema Suppression Test U was applied to the dorsal skin of 10 dehaired Hartley guinea pigs.
Irradiation with two times the minimum erythema dose of ultraviolet rays in the VB region is performed at two locations each. The sample was applied 24 hours before and immediately after irradiation, the sample application site and the base application site were set, and 24 hours later, the erythema state was evaluated according to the following criteria.
【0027】[0027]
【表2】 [Table 2]
【0028】(5)光パッチ試験 被験者25名の前腕屈側部皮膚に試料0.05gを塗布
した直径1.0cmのパッチ板を用いて24時間クロー
ズドパッチを行った後、夏期の太陽光を6時間(1日3
時間で2日間)照射した。(5) Optical patch test 25 subjects were subjected to closed patch for 24 hours using a patch plate having a diameter of 1.0 cm, which was prepared by applying 0.05 g of the sample to the skin on the forearm flexor side, and then exposed to sunlight in summer. 6 hours (3 a day
For 2 days).
【0029】評価は、下記の判定基準に従い、被験者2
5名の皮膚の状態を評価判定した。判定結果は、照射2
4時間後に、(±)以上の人数で示した。The evaluation was carried out by subject 2 according to the following criteria.
The skin condition of 5 persons was evaluated and judged. Judgment result is irradiation 2
After 4 hours, the number of people was (±) or more.
【0030】[0030]
【表3】 (6)官能試験 被験者20名が試料を10日間連用した後の試料の特性
を評価した。[Table 3] (6) Sensory test Twenty test subjects evaluated the characteristics of the sample after continuously using the sample for 10 days.
【0031】評価は湿潤性、親和性等のアンケート項目
に対し、「皮膚に潤いが生じた」、「皮膚への親和性が
良い」、と回答した人数で示した。The evaluation was shown by the number of respondents who answered that "the skin was moisturized" and "the affinity to the skin was good" for questionnaire items such as wettability and affinity.
【0032】 実施例1〜3、比較例1〜4 二相型ローション 表4の原料組成において、表4に記載の如く有効成分を
配合して、二相型ローションを調製し、前記の諸試験を
実施した。Examples 1 to 3 and Comparative Examples 1 to 4 Two-Phase Lotion In the raw material composition of Table 4, the active ingredients were blended as shown in Table 4 to prepare a two-phase lotion, and the above-mentioned various tests Was carried out.
【0033】[0033]
【表4】 [Table 4]
【0034】[0034]
【表5】 [Table 5]
【0035】(1)調製法 表4に記載のB成分をA成分中に、C成分をD成分中に
均一に溶解した後、A成分とD成分を均一に混合攪拌分
散し次いで容器に充填する。使用時には内容物を均一に
振盪分散して使用する。(1) Preparation method Component B shown in Table 4 is uniformly dissolved in component A and component C is uniformly dissolved in component D, and then component A and component D are uniformly mixed and stirred, and then dispersed in a container. To do. At the time of use, the contents should be evenly dispersed by shaking.
【0036】(2)特性 諸試験を実施した結果を表5に記載した。表5に示す如
く、比較例1は諸試験において良好な結果は示さなかっ
た。(2) Characteristics Table 5 shows the results of various tests. As shown in Table 5, Comparative Example 1 did not show good results in various tests.
【0037】実施例1〜3の本発明の美白化粧料は諸試
験の総てにおいて明らかに良好な結果を示し、ヒト皮膚
での諸試験において皮膚刺激は生じなかった。The whitening cosmetics of the present invention of Examples 1 to 3 showed clearly good results in all the tests, and no skin irritation occurred in the tests on human skin.
【0038】 実施例4〜7、比較例5〜7 スキンクリーム 表6の原料組成において、表7に記載の如く有効成分を
配合して、スキンクリームを調製し、前記の諸試験を実
施した。Examples 4 to 7 and Comparative Examples 5 to 7 Skin Cream In the raw material composition of Table 6, active ingredients were blended as shown in Table 7 to prepare a skin cream, and the above-mentioned various tests were carried out.
【0039】[0039]
【表6】 [Table 6]
【0040】[0040]
【表7】 [Table 7]
【0041】(1)調製法 表6に記載のB成分をA成分に混合し、C成分をD成分
にそれぞれ均一に加熱溶解して温度を80℃にする。次
いで、A成分中にD成分を注入乳化した後、攪拌しなが
ら300 Cまで冷却する。(1) Preparation method Component B shown in Table 6 is mixed with component A, and component C is uniformly dissolved in component D by heating to bring the temperature to 80 ° C. Then, after injecting and emulsifying the D component in the A component, the mixture is cooled to 300C with stirring.
【0042】(2)特性 諸試験を実施した結果を表7に示した。表7に示す如
く、実施例4〜6は、諸試験の総てにおいて明らかに良
好な結果を示し、ヒト皮膚での諸試験において良好な結
果を示し、皮膚刺激は生じなかった。(2) Characteristics Table 7 shows the results of various tests. As shown in Table 7, Examples 4 to 6 clearly showed good results in all of the tests, good results in the tests on human skin, and no skin irritation occurred.
【0043】以上記載の如く、本発明は紫外線による皮
膚の炎症抑制効果に優れ、メラニン色素の産生抑制効
果、皮膚の色素沈着の速やかな淡色化効果及び、皮膚刺
激が無い有用な使用感の優れた美白化粧料を提供するこ
とは明らかである。As described above, the present invention is excellent in the effect of suppressing the inflammation of the skin by ultraviolet rays, the effect of suppressing the production of melanin pigment, the effect of rapidly lightening the skin pigmentation, and the excellent usability without skin irritation. It is clear to provide whitening cosmetics.
Claims (1)
ことを特徴とする美白化粧料。1. A whitening cosmetic composition comprising a serum deproteinization product and glabridin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5047555A JPH06239730A (en) | 1993-02-13 | 1993-02-13 | Whitening cosmetic |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5047555A JPH06239730A (en) | 1993-02-13 | 1993-02-13 | Whitening cosmetic |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH06239730A true JPH06239730A (en) | 1994-08-30 |
Family
ID=12778433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP5047555A Pending JPH06239730A (en) | 1993-02-13 | 1993-02-13 | Whitening cosmetic |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH06239730A (en) |
-
1993
- 1993-02-13 JP JP5047555A patent/JPH06239730A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5937965B2 (en) | Full seed extract of Moringa species and its use in cosmetic and / or dermatological compositions | |
| US8722027B2 (en) | Method for preparing broussonetia kazinoki extract | |
| JPH0892057A (en) | Cosmetics containing coffee tree seed extract | |
| KR101078888B1 (en) | A cosmetic composition comprising tissue cultured Echinaceae adventitious roots and an preparing method thereof | |
| KR101017586B1 (en) | Cosmetic composition for skin whitening | |
| KR100926073B1 (en) | Cosmetic composition for exfoliation containing vitamin C and zinnia flower extract | |
| KR102085052B1 (en) | Composition for anti-inflammatory or moisturizing on skin comprising plant extract | |
| KR100468434B1 (en) | Cosmetic Compositions Comprising Vitamin C or Derivatives thereof Areca catechu L extract for Preventing Skin Aging | |
| KR20020062513A (en) | rose petal extract with skin whitening function and skin whitening cosmetic composition containg the same | |
| JP2731329B2 (en) | Skin cosmetics | |
| JP2702860B2 (en) | Skin cosmetics | |
| JPH03200708A (en) | Dermal external agent | |
| JPH06239730A (en) | Whitening cosmetic | |
| JP3649889B2 (en) | Whitening cosmetics | |
| JP2942409B2 (en) | Whitening cosmetics | |
| KR0140293B1 (en) | The cosmetic compositions containing codonopsis lanceolata extract | |
| KR20080111299A (en) | External preparation composition for skin whitening containing camphorol-3,7-O-alpha-L-diramnopyranoside | |
| KR102030419B1 (en) | A composition comprising graviola having inhibitory effect on induction of grey hair and positive effect on induction of black hair | |
| KR102644064B1 (en) | A cosmetic composition for skin wrinkle improvement containing mixed extracts of grape, olive leaf and myrrh as active ingredients | |
| JP3197651B2 (en) | Skin cosmetics | |
| KR100681700B1 (en) | Cosmetic composition for skin whitening containing Saint-Quinolide A and gluconic acid as active ingredients | |
| KR102727827B1 (en) | Composition for improving pore of skin comprising liquid extracted from Lindera obtusiloba | |
| JPH0710738A (en) | Beautifying cosmetic | |
| KR100821482B1 (en) | Whitening skin external composition | |
| JPH06206812A (en) | Skin cosmetic |